NO975366L - Vaksine sammensetning inneholdende polyribosylribitol fosfat og fremgangsmåte for fremstilling derav - Google Patents

Vaksine sammensetning inneholdende polyribosylribitol fosfat og fremgangsmåte for fremstilling derav

Info

Publication number
NO975366L
NO975366L NO975366A NO975366A NO975366L NO 975366 L NO975366 L NO 975366L NO 975366 A NO975366 A NO 975366A NO 975366 A NO975366 A NO 975366A NO 975366 L NO975366 L NO 975366L
Authority
NO
Norway
Prior art keywords
preparation
composition containing
vaccine composition
polyribosylribitol phosphate
polyribosylribitol
Prior art date
Application number
NO975366A
Other languages
English (en)
Other versions
NO319579B1 (no
NO975366D0 (no
Inventor
Francois Arminjon
Jean-Rene Cartier
Original Assignee
Pasteur Merieux Serums Vacc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9479510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO975366(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pasteur Merieux Serums Vacc filed Critical Pasteur Merieux Serums Vacc
Publication of NO975366L publication Critical patent/NO975366L/no
Publication of NO975366D0 publication Critical patent/NO975366D0/no
Publication of NO319579B1 publication Critical patent/NO319579B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
NO19975366A 1995-05-24 1997-11-21 Vaksine sammensetning inneholdende hoymolekylaert polyribosylribitolfosfat, og fremgangsmate for fremstilling derav NO319579B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9506417A FR2734484B1 (fr) 1995-05-24 1995-05-24 Composition vaccinale liquide et procede de fabrication
PCT/FR1996/000791 WO1996037222A1 (fr) 1995-05-24 1996-05-24 Composition vaccinale comprenant du polyribosylribitol phosphate et son procede de fabrication

Publications (3)

Publication Number Publication Date
NO975366L true NO975366L (no) 1997-11-21
NO975366D0 NO975366D0 (no) 1997-11-21
NO319579B1 NO319579B1 (no) 2005-08-29

Family

ID=9479510

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19975366A NO319579B1 (no) 1995-05-24 1997-11-21 Vaksine sammensetning inneholdende hoymolekylaert polyribosylribitolfosfat, og fremgangsmate for fremstilling derav
NO2011019C NO2011019I2 (no) 1995-05-24 2011-09-19 Vaksine omfattende antigenet PRP-T koplet til et tetanus anatoksin

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2011019C NO2011019I2 (no) 1995-05-24 2011-09-19 Vaksine omfattende antigenet PRP-T koplet til et tetanus anatoksin

Country Status (25)

Country Link
US (1) US6333036B1 (no)
EP (1) EP0828511B1 (no)
JP (1) JPH11505824A (no)
KR (1) KR100404312B1 (no)
CN (1) CN1152715C (no)
AT (1) ATE207365T1 (no)
BR (1) BR9608810C8 (no)
CA (1) CA2218764C (no)
CZ (1) CZ289810B6 (no)
DE (2) DE122011100030I1 (no)
DK (1) DK0828511T3 (no)
EA (1) EA000411B1 (no)
ES (1) ES2162067T3 (no)
FR (1) FR2734484B1 (no)
GR (1) GR3037011T3 (no)
HU (1) HU223941B1 (no)
LU (1) LU91924I2 (no)
NL (1) NL300231I2 (no)
NO (2) NO319579B1 (no)
NZ (1) NZ309829A (no)
PL (1) PL185846B1 (no)
PT (1) PT828511E (no)
SK (1) SK282500B6 (no)
TR (1) TR199701424T1 (no)
WO (1) WO1996037222A1 (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020054884A1 (en) 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
US6974581B1 (en) * 1998-12-15 2005-12-13 Aventis Pasteur Limited Multi-component vaccine comprising at least two antigens from haemophilus influenzae to protect against disease
IL145209A0 (en) 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
EP1674087A1 (en) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists
FR2828406B1 (fr) 2001-08-08 2005-06-24 Aventis Pasteur Composition vaccinale bivalente havi
DK2353608T3 (da) 2002-10-11 2020-02-10 Novartis Vaccines And Diagnostics S R L Polypeptid-vacciner til bred beskyttelse mod hypervirulente meningokok-linjer
DK1587537T3 (da) 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
GB0313916D0 (en) * 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
SI1670506T1 (sl) 2003-10-02 2013-03-29 Novartis Ag Tekoča cepiva proti multiplim meningokoknim seroskupinam
EP1689721B1 (en) * 2003-11-26 2010-07-14 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
GB0405787D0 (en) * 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
SI1740217T1 (sl) 2004-04-30 2011-10-28 Novartis Ag Konjugirano meningokokno cepljenje
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
KR101540920B1 (ko) * 2007-07-26 2015-08-03 사노피 파스퇴르 리미티드 항원-애주번트 조성물 및 방법
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
PE20100365A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
PE20100366A1 (es) 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
US7814991B2 (en) * 2009-01-28 2010-10-19 Gas Technology Institute Process and apparatus for subterranean drilling
CA2756522C (en) 2009-03-24 2018-06-26 Novartis Ag Adjuvanting meningococcal factor h binding protein
MA34084B1 (fr) * 2010-03-29 2013-03-05 Novartis Ag Composition comprenant le peptide amyloïde bêta 1-6 couplé à une particule de type virus et un adjuvant
CN103442730B (zh) 2011-01-05 2016-08-17 巴拉特生物技术国际有限公司 组合七价疫苗
EP2863943B1 (en) 2013-03-08 2016-07-13 Crucell Holland B.V. Acellular pertussis vaccine
JP7526880B2 (ja) 2021-04-20 2024-08-01 Ｋｍバイオロジクス株式会社 ６種混合液状ワクチン組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1209036A (en) * 1982-08-20 1986-08-05 Joseph S.C. Kuo Combined haemophilus influenzae and diphtheria, pertussis, tetanus vaccine
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
EP0320942A3 (en) * 1987-12-18 1989-10-04 American Cyanamid Company Novel polysaccharides novel macromolecular conjugates of the polysaccharides
GB9202219D0 (en) * 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
JP3626996B2 (ja) * 1992-05-23 2005-03-09 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム Ｂ型肝炎表面抗原および他の抗原からなる複合ワクチン

Also Published As

Publication number Publication date
CN1152715C (zh) 2004-06-09
FR2734484A1 (fr) 1996-11-29
MX9709011A (es) 1998-03-31
FR2734484B1 (fr) 1997-06-27
SK282500B6 (sk) 2002-10-08
ATE207365T1 (de) 2001-11-15
CN1190898A (zh) 1998-08-19
CA2218764C (fr) 2011-01-11
BR9608810A (pt) 1999-08-31
HUP9901432A3 (en) 2000-03-28
CZ359797A3 (cs) 1999-06-16
LU91924I2 (fr) 2012-02-21
CZ289810B6 (cs) 2002-04-17
WO1996037222A1 (fr) 1996-11-28
ES2162067T3 (es) 2001-12-16
EA199700419A1 (ru) 1998-06-25
NO2011019I2 (no) 2015-05-18
PL323457A1 (en) 1998-03-30
TR199701424T1 (xx) 1998-03-21
EA000411B1 (ru) 1999-06-24
JPH11505824A (ja) 1999-05-25
PL185846B1 (pl) 2003-08-29
SK152997A3 (en) 1998-07-08
NL300231I1 (nl) 2006-07-03
DE69620271T2 (de) 2002-07-18
EP0828511A1 (fr) 1998-03-18
NO2011019I1 (no) 2011-09-26
NO319579B1 (no) 2005-08-29
BR9608810C8 (pt) 2014-07-08
AU708777B2 (en) 1999-08-12
EP0828511B1 (fr) 2001-10-24
GR3037011T3 (en) 2002-01-31
US6333036B1 (en) 2001-12-25
CA2218764A1 (fr) 1996-11-28
NO975366D0 (no) 1997-11-21
HUP9901432A2 (hu) 1999-08-30
AU6008696A (en) 1996-12-11
KR19990014919A (ko) 1999-02-25
DE122011100030I1 (de) 2011-12-08
DK0828511T3 (da) 2002-02-18
NL300231I2 (nl) 2006-09-01
HK1017251A1 (en) 1999-11-19
PT828511E (pt) 2002-02-28
DE69620271D1 (de) 2002-05-02
NZ309829A (en) 1999-06-29
HU223941B1 (hu) 2005-03-29
KR100404312B1 (ko) 2004-02-11

Similar Documents

Publication Publication Date Title
NO975366D0 (no) Vaksine sammensetning inneholdende polyribosylribitol fosfat og fremgangsmåte for fremstilling derav
IS3753A7 (is) Endurbætt aðferð og samsetning bóluefnis
HUP0301413A1 (hu) Vakcinakészítmények
HUP9900061A1 (hu) Alumínium-foszfátra adszorbeált konjugált poliszacharid antigént tartalmazó vakcinakompozíciók
ATE446107T1 (de) Immunogenes beta-propionamido-gebundenes polysaccharid-protein konjugat geeignet als impfstoff und hergestellt bei verwendung von n- acryloyliertem polysaccharid
ATE19734T1 (de) Heamophilus influenzae b polysaccharid exotoxoid konjugat-impfstoff.
TW200514569A (en) Vaccine composition
CA2071811A1 (en) Improved meningococcal polysaccharide conjugate vaccine
IL77293A (en) Stable,covalently-coupled,polysaccharide-protein conjugates comprising neutral polysaccharides and immunogenic proteins coupled through bigeneric spacers,methods for preparing them and pharmaceutical compositions containing them
ITFI920058A1 (it) Composti coniugati formati da proteine heat shock (hsp) e oligo-polisaccaridi, loro uso per la produzione di vaccini.
KR920003982A (ko) 면역원성 콘쥬게이트 및 이를 함유하는 백신 조성물
SE9600716D0 (sv) Adhesion inhibitors, preparation comprising them and method for producing them
NO974727D0 (no) Immunogene og immunostimulatoriske oligosakkarid sammensetninger og fremgangsmåter for fremstilling derav
ES2000140A6 (es) Procedimiento para preparar vacunas conjugadas no toxicas contra infecciones por bacterias gram-negativas
AU3313789A (en) Haemophilus influenza type B oxidized polysaccharide-outer membrane protein conjugate vaccine
EP0320942A3 (en) Novel polysaccharides novel macromolecular conjugates of the polysaccharides
NO913131L (no) Immunogene konjugater av ikke-toksisk oligosakkarid fra bordetella pertussis lipoolysakkarid.
ATE206619T1 (de) Komplex aus antigen und zellbestandteil, verfahren zur dessen herstellung und therapeutische verwendungen

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: PEDIACEL; NAT. REG. NO/DATE: 09-7174 20110321; FIRST REG. NO/DATE: PL06745/0120 20021016

Spc suppl protection certif: 2011019

Filing date: 20110919

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: PEDIACEL; NAT. REG. NO/DATE: 09-7174 20110321; FIRST REG. NO/DATE: PL06745/0120 20021016

Spc suppl protection certif: 2011019

Filing date: 20110919

Extension date: 20171016

MK1K Patent expired